A large-scale, long-term, prospective post-marketing surveillance of Pitavastatin (LIVALO® Tablet) - LIVALO effectiveness and safety (LIVES) study interim (52 weeks) report

Japanese Pharmacology and Therapeutics

Volumn 36, Issue 1, 2008, Pages 9-28

  Kurihara, Yuji ^a   Douzono, Takashi ^a   Kawakita, Koji ^a   Nachi, Shinobu ^a   Nagasaka, Yoshimasa ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

Effectiveness; HMG CoA reductase inhibitor; Long term study; Pitavastatin; Post marketing surveillance; Safety

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; JAPAN; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; SIDE EFFECT;

EID: 56049106880     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim-Forsch/Drug Res 1997; 47 (II): 904-9.
2. Morikawa S, Umetani M, Nakagawa S, yamazaki H, Suganami H, Inoue K, et al. Relative induction of mRNA for HMG-CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000; 7: 138-44.
3. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 1999: 146: 259-70.
4. Japanese source.
5. Fujino H, Yamada I, Kojima J, Hirano M, Matsumoto H, Yoneda M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human. Xenobio Metabol and Dispos 1999; 14 (6): 415-24.
6. Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Arzneim-Forsch/Drug Res 2002; 52: 745-53.
7. Japanese source.
8. Japanese source.
9. Japanese source.
10. Japanese source.
11. Japanese source.
12. Japanese source.
13. Japanese source.
14. Japanese source.
15. Japanese source.
16. Japanese source.
17. Pasternak RC, Grundy SM, Smith SC Jr, Cleeman JI, Bairey-Merz CN, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 568-73.